small molecule

KYPROLIS

CARFILZOMIB

Loss of exclusivityAugust 2033latest FDA-listed patent expiry

CompanyONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC

Drug detail

Brand name	KYPROLIS
Active ingredient	CARFILZOMIB
Strength	60MG/VIAL
Dosage form	POWDER
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	July 2012
Marketing status	RX

Listed patents

Patent	Expires	Type
9493582*PED	August 2033	—
9493582	February 2033	product
RE47954*PED	April 2030	—
RE47954	October 2029	use U-3449
7737112*PED	June 2028	—
7737112	December 2027	product
7417042*PED	January 2027	—
7417042	July 2026	substance, product

Regulatory exclusivity

Code	Expires
PED	November 2028
M-14	May 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC